Abbott's Exact Sciences buy, Blackstone and TPG's Hologic acquisition, and Water's BD transaction could herald a busy 2026 ...

The US Food and Drug Administration cleared a number of molecular tests and immunoassays, as well as a clinical chemistry and a cellular deformation test.

The new financial agreements include $5 million of new term-loan proceeds to strengthen liquidity and funding for continued investment in product development.

The digital revolution is now more quickly transforming pathology lab workflows, pointing towards accelerating adoption in the coming years.

NEW YORK – Fulgent Genetics announced on Monday that it has entered into a definitive agreement to acquire lab service provider StrataDx, as well as certain assets of Bako Diagnostics. Fulgent said it ...

The deal gives clinicians in PathNet's national lab network access to Valar's AI-powered Vesta diagnostic portfolio for non-muscle invasive bladder cancer.

Last week, readers were most interested in a story about the reasons behind the rapid adoption of BioMérieux's SpotFire syndromic qPCR instrument.

Approaches incorporating rapid or digital PCR, CRISPR, syndromic testing, and multimodal systems reached new milestones this year.

During the year, the industry saw continued consolidation, the end of a key advisory body, the rise in DTC testing and advanced diagnostics, and another stab at PAMA reform.

Under the collaboration, the parties will run a preclinical study evaluating Singlera and Breakthrough's BT-Reveal Early Pancreatic Cancer Test.

The company has developed a method to detect circulating tumor DNA in surgical drain fluid from postoperative patients to detect molecular residual disease.